//platform.linkedin.com/in.js

(Washington DC, May 25th 2016): Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by airflow limitation and loss of lung function that is not completely reversible. It is a leading cause of morbidity, mortality and hospitalizations in the elderly, accounting for 726,000 hospitalizations and 1.5 million emergency department visits in the US in year 2000.  Though non-invasive ventilation (NIV) is considered a standard of care for in-hospital treatment of acute COPD exacerbations, long-term use of NIV for management of chronic COPD has been limited by several factors.

Boston Strategic Partners, Inc. (BSP) researchers Dr. Fred Peyerl, Dr. Sibyl Munson, and Dr. Aditi Ravindranath in collaboration with Dr. Steven Coughlin (Philips Respironics) and Dr. Teofilo Lee-Chiong (National Jewish Health, Denver) implemented a budget impact model to calculate the economic impact associated with use of Advanced-NIV versus either no NIV or a respiratory assist device with bi-level pressure capacity (RAD-NIV) in severe COPD patients, from the payer and the hospital perspectives.

The presentation will be on display at ISPOR today between 8.15am to 2.45 pm. The poster author discussion hour is scheduled at 1.45pm to 2.45 pm. Visit the authors at booth 32 to learn more about the association between the prevalence of COPD comorbidities and readmission rates. The research is supported by detailed analyses of EHR database which contains information about 60 million unique patients over a 15 year timeframe. More information on this database can be found here.

Please check out our events section for the full list of presentation titles and timetable.

To schedule a meeting with our team, please email us at info@bostonsp.com. We look forward to discussing ideas and insights on health economics and outcomes research and ways to support your business and clinical needs.

About ISPOR

Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) advances the policy, science, and practice of pharmacoeconomics (health economics) and outcomes research (the scientific discipline that evaluates the effect of health care interventions on patient well-being including clinical, economic, and patient-centered outcomes).

(Source: http://www.ispor.org/about-ispor.asp)